全文获取类型
收费全文 | 266篇 |
免费 | 21篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 7篇 |
妇产科学 | 6篇 |
基础医学 | 45篇 |
口腔科学 | 4篇 |
临床医学 | 24篇 |
内科学 | 35篇 |
皮肤病学 | 2篇 |
神经病学 | 45篇 |
特种医学 | 15篇 |
外科学 | 20篇 |
综合类 | 1篇 |
一般理论 | 1篇 |
预防医学 | 19篇 |
药学 | 15篇 |
肿瘤学 | 45篇 |
出版年
2024年 | 1篇 |
2023年 | 9篇 |
2022年 | 2篇 |
2021年 | 10篇 |
2020年 | 11篇 |
2019年 | 16篇 |
2018年 | 11篇 |
2017年 | 9篇 |
2016年 | 10篇 |
2015年 | 5篇 |
2014年 | 13篇 |
2013年 | 17篇 |
2012年 | 30篇 |
2011年 | 32篇 |
2010年 | 21篇 |
2009年 | 11篇 |
2008年 | 10篇 |
2007年 | 15篇 |
2006年 | 8篇 |
2005年 | 8篇 |
2004年 | 9篇 |
2003年 | 3篇 |
2002年 | 4篇 |
1998年 | 1篇 |
1995年 | 2篇 |
1994年 | 1篇 |
1991年 | 1篇 |
1990年 | 2篇 |
1987年 | 3篇 |
1985年 | 3篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1974年 | 2篇 |
1968年 | 1篇 |
1966年 | 1篇 |
1965年 | 1篇 |
排序方式: 共有287条查询结果,搜索用时 31 毫秒
1.
2.
Renske Oegema George McGillivray Richard Leventer Anne‐Gaëlle Le Moing Nadia Bahi‐Buisson Angela Barnicoat Simone Mandelstam David Francis Fiona Francis Grazia M. S. Mancini Sanne Savelberg Gijs van Haaften Kshitij Mankad Maarten H. Lequin 《American journal of medical genetics. Part C, Seminars in medical genetics》2019,181(4):627-637
3.
4.
Renske M.T. ten Ham Merel van Nuland Rick A. Vreman Laurens G. de Graaf Hilde Rosing André M. Bergman Alwin D.R. Huitema Jos H. Beijnen Anke M. Hövels 《Value in health》2021,24(1):121-128
ObjectivesAbiraterone acetate is registered for the treatment of metastatic castration-sensitive and resistant prostate cancer (mCRPC). Treatment outcome is associated with plasma trough concentrations (Cmin) of abiraterone. Patients with a plasma Cmin below the target of 8.4 ng/mL may benefit from treatment optimization by dose increase or concomitant intake with food. This study aims to investigate the cost-effectiveness of monitoring abiraterone Cmin in patients with mCRPC.MethodsA Markov model was built with health states progression-free survival, progressed disease, and death. The benefits of monitoring abiraterone Cmin followed by a dose increase or food intervention were modeled via a difference in the percentage of patients achieving adequate Cmin taking a healthcare payer perspective. Deterministic and probabilistic sensitivity analyses were performed to assess uncertainties and their impac to the incremental cost-effectiveness ratio (ICER).ResultsMonitoring abiraterone followed by a dose increase resulted in 0.149 incremental quality-adjusted life-years (QALYs) with €22 145 incremental costs and an ICER of €177 821/QALY. The food intervention assumed equal effects and estimated incremental costs of €7599, resulting in an ICER of €61 019/QALY. The likelihoods of therapeutic drug monitoring (TDM) with a dose increase or food intervention being cost-effective were 8.04%and 81.9%, respectively.ConclusionsMonitoring abiraterone followed by a dose increase is not cost-effective in patients with mCRPC from a healthcare payer perspective. Monitoring in combination with a food intervention is likely to be cost-effective. This cost-effectiveness assessment may assist decision making in future integration of abiraterone TDM followed by a food intervention into standard abiraterone acetate treatment practices of mCRPC patients. 相似文献
5.
6.
Renske Kruizinga Michael Scherer-Rath Hans J.B.A.M. Schilderman Christina M. Puchalski Hanneke H.W.M. van Laarhoven 《Journal of pain and symptom management》2018,55(3):1035-1040
In this article, we aimed to set out current problems that hinder a fully fledged integration of spiritual and medical care, which address these obstacles. We discuss the following five statements: 1) spiritual care requires a clear and inclusive definition of spirituality; 2) empirical evidence for spiritual care interventions should be improved; 3) understanding patients' experiences of contingency is paramount to deliver effective spiritual care; 4) attention to spiritual needs of patients is a task for every health care practitioner; 5) courses on spirituality and spiritual care should be mandatory in the medical curriculum. Current problems might be overcome by speaking each other's language, which is crucial in interdisciplinary research and in good interdisciplinary collaboration. Using a clear and inclusive definition of spirituality and substantiating spiritual care using medical standards of evidence-based practice is a way to speak each other's language and to increase mutual understanding. Furthermore, including spirituality in the medical curriculum would raise awareness of medical practitioners for their task of attending to patients' spiritual needs and, subsequently, to better and more appropriate referral for spiritual care. 相似文献
7.
8.
9.
10.
Christoph Kraus Darin Quach David M. Sholtes Erhan Kavakbasi Renske De Zwaef Maxine Dibué John Zajecka Bernhard T. Baune 《Neuromodulation》2022,25(3):316-326
BackgroundA substantial number of patients with major depressive disorder (MDD) do not sufficiently remit after the first lines of antidepressant treatments, making them vulnerable to poor clinical outcomes. Patients who have not had adequate resolution of their depressive symptoms after four antidepressant treatments and/or have been experiencing their current episode of MDD for two years or more (with insufficient responses to adequate antidepressant treatments) should be evaluated for antidepressant vagus nerve stimulation (VNS Therapy). Adjunctive VNS Therapy is a promising long-term treatment option for patients with difficult-to-treat depression (DTD), offering significantly improved remission rates in comparison with usual treatments. However, VNS Therapy requires specialized treatment centers to support patients.Materials and MethodsIn this narrative review, we aim to outline the necessary steps for setting up an antidepressant VNS Therapy service in an efficient manner.ResultsEstablishing a VNS Therapy service requires several high-level considerations: initiation of a collaborative multidisciplinary team of health care professionals; developing a surgical pathway for implantation; consideration of reimbursement and health care coverage; setting up a specialist clinic to identify optimal candidates for VNS Therapy; educating patients and their families about VNS Therapy; and training health care providers on patient-specific VNS Therapy treatment and long-term treatment management.ConclusionsAntidepressant VNS Therapy is a promising treatment option for the long-term treatment of patients with DTD. We have successfully initiated four VNS Therapy service centers for DTD in the United States, Austria, and Germany. Based on our experiences and lessons learned, herein, we have provided advice to psychiatric centers planning to set up a VNS Therapy service for their patients with DTD. 相似文献